Alvotech (ALVO) Stock Price & How to Invest

Alvotech develops and manufactures biosimilars, which are approved copies of biologic medicines whose patents have run out, and then hands the selling to partners rather than building its own sales force. Teva covers the United States, Advanz Pharma covers Europe, the UK, Switzerland, Canada and Australia, Dr. Reddy's carries denosumab and is co-developing a Keytruda biosimilar, and Sandoz picked up Canadian and ANZ rights in early 2026. Five biosimilars now produce revenue: adalimumab, ustekinumab, golimumab, aflibercept and denosumab. Money arrives in two very different shapes, product supply to those partners and lumpy licensing and milestone payments, which is why half-year comparisons swing hard. First-half 2026 revenue was about $211.9 million, split almost evenly between roughly $105.9 million of product and $105.7 million of licensing, against $306.1 million a year earlier when milestones happened to land in the period.

The investment picture turns on one date. On November 2, 2025, the FDA issued a complete response letter for AVT05, the golimumab biosimilar, and the shares fell about 34% to $5.03 the next day. Related manufacturing findings at the Reykjavik plant also held up AVT06 (aflibercept) and AVT03 (denosumab). That inspection has since closed with a voluntary action indicated classification, the applications were resubmitted in June 2026, and the FDA review goal points to decisions around December 4. Management reaffirmed 2026 guidance of $650 million to $700 million in revenue and $180 million to $220 million in adjusted EBITDA, but only $46.9 million of that EBITDA arrived in the first half, so the guide leans almost entirely on the fourth quarter. Behind it sits about $1.31 billion of borrowings, $142.8 million of cash at June 30, a $165 million equity raise in June that diluted existing holders, and a new $75 million term loan priced at 12.50%. Barclays moved the stock two notches to Overweight in September with an $8 target; the broader analyst average sits near $6.80.

Leverage is the dominant risk: roughly $1.31 billion of borrowings against $142.8 million of cash mid-year, a net-debt-to-adjusted-EBITDA ratio above 9x at the end of 2025, and a new term loan carrying 12.50% cash interest maturing December 2027. Management has stated the company remains a going concern while noting it may need further financing if cash generation lags, and the June equity raise showed what closing that gap costs existing holders. The 2026 guide requires a fourth quarter far larger than the first half delivered, which makes it unusually dependent on approvals and milestone recognition arriving on schedule. Several plaintiff law firms, including Rosen, Hagens Berman and Levi and Korsinsky, have publicised investigations into the disclosures that preceded the November 2025 complete response letter, though no filed complaint or lead plaintiff deadline has been made public. Underneath all of it, biosimilar pricing erodes quickly once several competitors clear the same molecule, so an approval that arrives into a crowded market is worth much less than the first one in.

5 analysts publish price targets on ALVO, averaging $6.80 against a $5.87 price as of September 2026, or +15.8%. The published targets run from $4.00 to $9.00, a wide spread, and the ratings split 6 buy, 1 hold, 0 sell. Over the last six months there has been 1 raise and 2 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full ALVO forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Alvotech. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Three FDA decisions in one December week. AVT05 (a biosimilar to Simponi and Simponi Aria), AVT06 (Eylea) and AVT03 (Prolia and Xgeva) were all resubmitted in June 2026 under a six month review clock that points to early December. The most optimistic published target, $9.00, assumes this works close to its best case.

The case against. Leverage is the dominant risk: roughly $1.31 billion of borrowings against $142.8 million of cash mid-year, a net-debt-to-adjusted-EBITDA ratio above 9x at the end of 2025, and a new term loan carrying 12.50% cash interest maturing December 2027. The most pessimistic target, $4.00, is roughly what ALVO is worth if this bites instead.

Read the full bull and bear case on ALVO, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Alvotech's investor relations page or your broker.

• Revenue (TTM): ~$495 million
• 2026 revenue guidance: ~$650M to $700M
• Adjusted EBITDA (H1 2026): ~$46.9 million
• Net loss (TTM): ~$180 million
• Market cap: ~$2.1 billion
• Net debt: ~$1.3 billion

Adding roughly $1.3 billion of net debt to a $2.1 billion market cap puts enterprise value near $3.4 billion, about 17 times the midpoint of 2026 adjusted EBITDA guidance and roughly 3 times guided revenue. Those multiples only hold if the second half arrives as guided, because the first half produced about a quarter of the full-year EBITDA target. The shares have traded between $2.94 and $9.25 over the past year, a range that says more about how the market prices the regulatory outcome than about the operating business.

Other names that sit close to ALVO: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get ALVO exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so ALVO sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where ALVO fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Alvotech is a genuine manufacturer with five products already selling, priced as a leveraged wager on a December regulatory decision that leaves little room for another delay.

Whether ALVO is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ALVO a buy or a sell?, and where the stock could go from here in the ALVO stock forecast.

For income investors, whether ALVO pays a dividend and how the payout looks is covered in does ALVO pay a dividend? And to weigh ALVO against a peer, read the full side-by-side comparisons: ALVO vs AMGN and ALVO vs ABBV.